Search Results - "Igarashi, Morio"

Effects of Angiotensin-Converting Enzyme Inhibitors or an Angiotensin Receptor Blocker in Combination With Aspirin and Cilostazol on In-stent Restenosis by Ujiie, Yuichi, Hirosaka, Akira, Mitsugi, Minoru, Ohwada, Takayuki, Igarashi, Morio, Kijima, Mikihiro, Komatsu, Nobuo, Hisa, Shinichi, Abe, Yukihiko, Tsuda, Tatsunori, Yaoita, Hiroyuki, Maehara, Kazuhira, Maruyama, Yukio

“…It remains to be determined whether adding an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) to antiplatelet…”
Get full text

ACUTE MYOCARDIAL INFARCTION IN FUKUSHIMA AREA OF JAPAN by MITSUGI, MINORU, KIJIMA, MIKIHIRO, SEINO, YOSHITANE, ABE, YUKIHIKO, FUJINO, AKIHISA, HIROSAKA, AKIRA, HISA, SHINICHI, KUBO, TAKAAKI, MAEYAMA, TADAMI, OHARA, NAOTO, ONO, MASAHIRO, OWADA, TAKAYUKI, SAITO, TOMIYOSHI, IGARASHI, MORIO, SATO, MASAHIKO, SUZUKI, SHIGEFUMI, TAMAGAWA, KAZUAKI, TSUDA, TATSUNORI, TSUDA, AKIHIRO, WATANABE, MASAYUKI, YUI, MITSURU, KOMATSU, NOBUO, NAKAZATO, KAZUHIKO, MARUYAMA, YUKIO

“…Although acute myocardial infarction (AMI) is the most serious coronary disease, the background of its onset and the mortality are not fully understood,…”
Get full text

GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide by Haas, Sylvia, Camm, John A., Harald, Darius, Steffel, Jan, Virdone, Saverio, Pieper, Karen, Brodmann, Marianne, Schellong, Sebastian, Misselwitz, Frank, Kayani, Gloria, Kakkar, Ajay K.

“…Background The G lobal A nticoagulant R egistry in the FIELD – A trial F ibrillation (GARFIELD-AF) is a worldwide non-interventional study of stroke prevention…”
Get full text

Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis by Akao, Masaharu, Yamashita, Takeshi, Suzuki, Shinya, Okumura, Ken

“…Dose reduction of apixaban is applied in atrial fibrillation (AF) patients fulfilling ≥ 2 of the following criteria: (1) age ≥ 80 years, (2) body weight ≤…”
Get full text